Relevance of Exomiser v14 rank-budget recovery of known diagnoses in ACG trios (Talos 2026) to "Reanalyse unresolved rare-disease cases"
- Use case
- Reanalyse unresolved rare-disease cases
- Assessed by
- Exomiser rank-budget recovery in ACG trios
- Relevance
- Proxy evidence
- Endpoint
- Known ACG trio diagnoses recovered by Exomiser v14 within all, top 10, top 5 and top 1 ranks, as the comparator to Talos
A ranked-list reanalysis comparator on the same ACG trios shows how many candidates must be reviewed to recover known diagnoses, set against Talos's unranked short list. It is proxy evidence: the diagnoses were known, a rank budget is not measured reviewer effort, and the denominator conflict (194 in the text, 190 in the Extended Data Fig. 1 legend) is unresolved.
1 reviewed evaluation
Evidence
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Evidence table
Inspect claims, sources and review details
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
18 evidence rows matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|---|---|
Citation locations1 values
| Automated reanalysis of genomic data for rare disease diagnostics at scale uc-clinical-20260930-source-talos: Results 'Comparison with other tools'; Methods 'Exomiser comparison'; Extended Data Fig. 1 legend Version: Nature Medicine 2026 final publication, 24 June 2026 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Comparison group talos2026-exomiser-acg Context-only references | Automated reanalysis of genomic data for rare disease diagnostics at scale uc-clinical-20260930-source-talos: Results 'Comparison with other tools'; Methods 'Exomiser comparison'; Extended Data Fig. 1 legend Version: Nature Medicine 2026 final publication, 24 June 2026 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Comparison title Exomiser v14 rank budget on known ACG trio diagnoses (Talos 2026) Context-only references | Automated reanalysis of genomic data for rare disease diagnostics at scale uc-clinical-20260930-source-talos: Results 'Comparison with other tools'; Methods 'Exomiser comparison'; Extended Data Fig. 1 legend Version: Nature Medicine 2026 final publication, 24 June 2026 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
Constraints2 values
| Automated reanalysis of genomic data for rare disease diagnostics at scale uc-clinical-20260930-source-talos: Results 'Comparison with other tools'; Methods 'Exomiser comparison'; Extended Data Fig. 1 legend Version: Nature Medicine 2026 final publication, 24 June 2026 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Endpoint Known ACG trio diagnoses recovered by Exomiser v14 within all, top 10, top 5 and top 1 ranks, as the comparator to Talos Context-only references | Automated reanalysis of genomic data for rare disease diagnostics at scale uc-clinical-20260930-source-talos: Results 'Comparison with other tools'; Methods 'Exomiser comparison'; Extended Data Fig. 1 legend Version: Nature Medicine 2026 final publication, 24 June 2026 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Claimed field links:assessed_by:uc-clinical-20260930-exomiser-acg-protocol Context-only references | Automated reanalysis of genomic data for rare disease diagnostics at scale uc-clinical-20260930-source-talos: Results 'Comparison with other tools'; Methods 'Exomiser comparison'; Extended Data Fig. 1 legend Version: Nature Medicine 2026 final publication, 24 June 2026 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Headline metric recall Context-only references | Automated reanalysis of genomic data for rare disease diagnostics at scale uc-clinical-20260930-source-talos: Results 'Comparison with other tools'; Methods 'Exomiser comparison'; Extended Data Fig. 1 legend Version: Nature Medicine 2026 final publication, 24 June 2026 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
Limitations5 values
| Automated reanalysis of genomic data for rare disease diagnostics at scale uc-clinical-20260930-source-talos: Results 'Comparison with other tools'; Methods 'Exomiser comparison'; Extended Data Fig. 1 legend Version: Nature Medicine 2026 final publication, 24 June 2026 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
Pinned records12 values
| Automated reanalysis of genomic data for rare disease diagnostics at scale uc-clinical-20260930-source-talos: Results 'Comparison with other tools'; Methods 'Exomiser comparison'; Extended Data Fig. 1 legend Version: Nature Medicine 2026 final publication, 24 June 2026 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Rationale A ranked-list reanalysis comparator on the same ACG trios shows how many candidates must be reviewed to recover known diagnoses, set against Talos's unranked short list. It is proxy evidence: the diagnoses were known, a rank budget is not measured reviewer effort, and the denominator conflict (194 in the text, 190 in the Extended Data Fig. 1 legend) is unresolved. Context-only references | Automated reanalysis of genomic data for rare disease diagnostics at scale uc-clinical-20260930-source-talos: Results 'Comparison with other tools'; Methods 'Exomiser comparison'; Extended Data Fig. 1 legend Version: Nature Medicine 2026 final publication, 24 June 2026 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
Sources and history
Release 2026-11-21-c8bea25e5abb · Record review: source checked
1 source record and release history
- Automated reanalysis of genomic data for rare disease diagnostics at scale · Original source · Nature Medicine 2026 final publication, 24 June 2026
Technical metadata and extraction receipts
Stable ID: use-case-mapping-rare-reanalysis-20261009-talos2026-exomiser-acg
- field
- links:assessed_by:uc-clinical-20260930-exomiser-acg-protocol
- value
- uc-clinical-20260930-exomiser-acg-protocol
- relevance
- proxy
- endpoint
- Known ACG trio diagnoses recovered by Exomiser v14 within all, top 10, top 5 and top 1 ranks, as the comparator to Talos
- rationale
- A ranked-list reanalysis comparator on the same ACG trios shows how many candidates must be reviewed to recover known diagnoses, set against Talos's unranked short list. It is proxy evidence: the diagnoses were known, a rank budget is not measured reviewer effort, and the denominator conflict (194 in the text, 190 in the Extended Data Fig. 1 legend) is unresolved.
- constraints
- Inspect every linked evaluation's source locator and preserved limitations before citing a result.; Do not combine these results with another protocol's results; cohorts, inputs and scoring units differ between sources.
- limitations
- Recall here is recovery of diagnoses that were already known. It is not new diagnostic yield.; The Results text gives 194 trio families with SNV or indel diagnoses, and every printed percentage matches 194 (172/194 = 88.7%, printed 89%; 127/194 = 65.5%, printed 65%). Only the Extended Data Fig. 1 legend gives N = 190, for the paired panels, which are not extracted.; Talos Table 1 uses 196 known ACG trio diagnoses of all variant types, so Talos and Exomiser recall have different denominators and sit in separate comparison groups.; Exomiser v14 with default configuration; data release, phenotype input and pathogenicity sources not stated.; A rank budget (top 1, 5 or 10) is not measured analyst effort.
- citation locators
- source id: uc-clinical-20260930-source-talos; locator: Results 'Comparison with other tools'; Methods 'Exomiser comparison'; Extended Data Fig. 1 legend
- source locator
- uc-clinical-20260930-source-talos: Results 'Comparison with other tools'; Methods 'Exomiser comparison'; Extended Data Fig. 1 legend
- revision
- 1
- reason
- Recorded from the rare-disease reanalysis use-case pass 2026-10-09 (data/omics/use-case-coverage-rare-reanalysis-20261009). Independently reviewed 2026-10-09 (docs/reviews/use-cases/unresolved-rare-disease-reanalysis-2026-10-09.md).
- comparison group
- talos2026-exomiser-acg
- comparison title
- Exomiser v14 rank budget on known ACG trio diagnoses (Talos 2026)
- headline metric
- recall
- reviewed evaluations
- uc-clinical-20260930-exomiser-acg-evaluation
- review
- method: source-hash-verification; ai-assisted-source-review; method note: Checked the endpoint against the use case's question, inputs, output and exclusions; checked proxy against the relevance definitions; checked the limitations against the source's stated caveats; checked the page grouping (comparison group, stratum order, headline metric) against the source tables. Checked every evaluation on the protocol (listed in reviewed_evaluations); none excluded.; reviewer: claude; reviewer note: Separate Claude review agent, independent of the extractor; no human review claimed; date: 2026-10-09; artifact sha256: 219ba75789e767341d642128750be600433764d5f271db8d7c0ffb5aa6a4d1dd; retrieval url: https://www.ebi.ac.uk/europepmc/webservices/rest/PMC13472938/fullTextXML; note: Proxy relevance confirmed. The 194 versus 190 conflict is narrowed to the Extended Data Fig. 1 legend; no stored result depends on 190. Not human scientific review and not clinical validation. The stored Talos source pins the publisher page; this review compared Table 1 and the Exomiser comparison text with the PMC copy (PMC13472938 full-text XML, SHA-256 219ba75789e767341d642128750be600433764d5f271db8d7c0ffb5aa6a4d1dd), and all 60 Talos Table 1 values and the 8 Exomiser counts and percentages match the stored results.
- pins
- record id: uc-clinical-20260930-exomiser-acg-evaluation; fields: status; links; attributes.origin; attributes.comparison; sha256: a0b507a5681c853818c304870863bd062ce3e8ebc9973099cab1daa02b286869; record id: uc-clinical-20260930-exomiser-acg-protocol; fields: status; name; description; facets; source_ids; links; attributes; sha256: c5e64ad3ccf51866981f4f5ea0100a923e4d986718560dd24ac9bae3997c8668; record id: uc-clinical-20260930-exomiser-all-count; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 3712aa7628bf47df0707f34ab2e13a0479eb3750e0df72b3880bccd9f64a1c3f; record id: uc-clinical-20260930-exomiser-all-percent; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 6b7de867d5564022be68c4db741ed70c99365d8a68fad244dad54c7dd509b365; record id: uc-clinical-20260930-exomiser-top1-count; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 18c0388c3e0288b2283376d0967d6d9b07fb8d2d031dcef732cbd54229f313fa; record id: uc-clinical-20260930-exomiser-top1-percent; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 758f49479e05f7162070f1556212ed8d23c643858cbda1e032bb67663fa647b7; record id: uc-clinical-20260930-exomiser-top10-count; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 36d4acb9169aae509747568ad78b84309102c81bd3fb084813b4ad068d032613; record id: uc-clinical-20260930-exomiser-top10-percent; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: b2b21db036e212bc5cf3baa7cfeab0de8eecc2304ab5113ae8c33f1e4e46172d; record id: uc-clinical-20260930-exomiser-top5-count; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 84dc4922c6af03bfbf3a7344b2a860c833d386bf5e8381cb76ffd5777f59d7d4; record id: uc-clinical-20260930-exomiser-top5-percent; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: c850ef0636b387de09df465fff8c3bb80aab7304fa38da68d0c4b310fc5fac22; record id: uc-clinical-20260930-source-talos; fields: status; attributes.artifact_sha256; sha256: 90df8425bea523bb170910a4e057d9c3d0132ce74c82212e202b6114f188b4f3; record id: use-case-unresolved-rare-disease-reanalysis; fields: status; name; description; facets; attributes.question; attributes.decision; attributes.inputs; attributes.output; attributes.exclusions; attributes.setting; attributes.clinical_scope; attributes.intended_users; sha256: 7a34a11b2cbb377f490c4a4a0cb9bedc53fdc88b132b4c695cdd7b612f97476e